Hyperthermia and targeting heat shock proteins: innovative approaches for neurodegenerative disorders and Long COVID

Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19

Published: Feb. 4, 2025

Neurodegenerative diseases (NDs) and Long COVID represent critical growing global health challenges, characterized by complex pathophysiological mechanisms including neuronal deterioration, protein misfolding, persistent neuroinflammation. The emergence of innovative therapeutic approaches, such as whole-body hyperthermia (WBH), offers promising potential to modulate underlying in NDs related conditions like COVID. WBH, particularly fever-range, enhances mitochondrial function, induces heat shock proteins (HSPs), modulates neuroinflammation—benefits that pharmacological treatments often struggle replicate. HSPs HSP70 HSP90 play pivotal roles folding, aggregation prevention, cellular protection, directly targeting pathological processes seen Alzheimer's, Parkinson's, Huntington's disease. Preliminary findings also suggest WBH's alleviate neurological symptoms COVID, where neuroinflammation serotonin dysregulation are prominent. Despite the absence robust clinical trials, implications WBH extend immune modulation restoration disrupted physiological pathways. However, dual nature hyperthermia's effects—balancing pro-inflammatory anti-inflammatory responses—emphasizes need for dose-controlled applications stringent patient monitoring minimize risks vulnerable populations. While shows interest, significant challenges remain. These include individual variability response, limited accessibility advanced technologies, standardized protocols. Future research must focus on targeted biomarker identification, personalized treatment strategies optimize efficacy integration into paradigms could mark a transformative step addressing these conditions.

Language: Английский

---

From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 28, 2025

The emergence of immunotherapies has revolutionized cancer treatment by leveraging the immune system to target malignancies, offering new hope where traditional therapies often fall short. Within this context, hyperthermia (HT) re-emerged as a promising adjunctive treatment, capable enhancing effectiveness radiotherapy, chemotherapy, and immunotherapy. HT influences both innate adaptive systems, activity cells such neutrophils, NK cells, dendritic while also modulating tumor microenvironment (TME) promote immunogenic cell death (ICD) reduce immunosuppressive conditions. These effects contribute transformation immunologically “cold” tumors into “hot” tumors, making them more susceptible immune-mediated destruction. Furthermore, can amplify efficacy checkpoint inhibitors (ICIs) improving infiltration, inducing damage-associated molecular pattern (DAMP) release, antigen presentation. Preclinical clinical studies support combination with ICIs, demonstrating improved outcomes in otherwise resistant tumors. However, full therapeutic potential different technologies allowing apply remains be fully understood, further research is needed optimize protocols, explore differential impacts local versus whole-body hyperthermia, identify biomarkers for patient stratification. This review underscores multifaceted role immunity its significantly enhance

Language: Английский

---

Whole-body hyperthermia as part of a multimodal treatment for patients with post-covid syndrome – a case series

International Journal of Hyperthermia, Journal Year: 2025, Volume and Issue: 42(1)

Published: May 7, 2025

Post-Covid syndrome (PCS) has been an ongoing challenge since the COVID-19 pandemic. Relatively little is known about effect of whole-body hyperthermia (WBH) in treatment PCS. We retrospectively analyzed data patients with PCS who were treated as inpatients a multimodal integrative therapy approach including WBH. The primary outcome comprised changes Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F) between T0 (at hospital admission) and T2 (four weeks after discharge), secondary outcomes Fatigue Impact Scale (FIS-D), Multidimensional Dyspnea Profile (MDP) Covid-Associated Symptoms (CAS) T0-T1 discharge) T0-T2. FACIT-F yielded significant increase (p < 0.001) (19.1 ± 8.4) (29.9 13.0) (primary outcome), indicating improved health status. While FIS-D CAS scores significantly T2, dyspnea parameters only T1. 63% respondents identified WBH effective treatment. Study results provide preliminary evidence for potentially positive effects setting this study, which it embedded approach. should be substantiated by future RCTs to identify specific individual components.

Language: Английский

---

Extracellular Microvesicles vs. Mitochondria: Competing for the Top Spot in Cardiovascular Regenerative Medicine

Stem Cell Reviews and Reports, Journal Year: 2024, Volume and Issue: 20(7), P. 1813 - 1818

Published: July 8, 2024

Language: Английский

---